Abstract :

Cisplatin (CP) is a potent anticancer agent used in cancer treatment. However, Cisplatin had ability to induce multiorgan toxicity including nephrotoxicity. This study aims to investigate the effect of vitamin E (Vit. E) and Vitamin C (vit. C) on nephrotoxicity induced by cisplatin in female rats.

Twenty Female white albino rats were divided to four groups, control, cisplatin, vit. E + cisplatin and vit. C + cisplatin. Cispatin (8 mg/kg as a single dose on the day on and second dose at 14 experimental day.vit. E was administered Intraperitoneal injection 3 days prior to cisplatin (8 mg/kg, i.p) injection two does same process for two weeks with two-week rest period. vitamin C (200 mg/kg), were administered Intraperitoneal injection 3 days prior to cisplatin (8 mg/kg, i.p) injection two does same process for two weeks with two-week rest period. The result of this study administration of cisplatin induced Necrosis of epithelial cells of renal tubules in cortex area led to form spaces filled with inflammatory cells forming a cluster in affected areas in the cisplatin treated group compared with vit. E + Cisplatin treated group which reduced nephrotoxicity by antioxidant activity of vitamin against cisplatin induced oxidative stress in these rats. However, vit. C + Cisplatin treated group showed mild nephroprotection. Necrosis of epithelial cells was observed in renal tubules with infiltration of inflammatory cells that formed small cluster near the glomerulus in cortex area. The study findings indicated that vitamin E exert protective effects against CP-induced nephrotoxicity, a finding which requires larger studies for confirmation. cisplatin treatment alone induced the upregulation of cytokeratin-8 (CK-8), a marker of tubular injury, co-treatment with Vit.E attenuated this effect, indicating protection of renal tubular integrity. Also,cisplatin treatment group showed positive expression of vimentin in cortical convoluted renal tubules and normal expression in glomerulus.

---

Keywords :

Cisplatin, cytokeratin-8, vimentin, vitamin C, Vitamin E

---

References :

1. Abdullah, M., Jamil, R. T., & Attia, F. N. (2023). Vitamin C (ascorbic acid). In StatPearls. StatPearls Publishing.
2. Alberts, A., Moldoveanu, E. T., Niculescu, A. G., & Grumezescu, A. M. (2025). Vitamin C: A comprehensive review of its role in health, disease prevention, and therapeutic potential. Molecules, 30(3), 748.
3. Alvarez Moreno, J. C., Bahmad, H. F., Febres-Aldana, C. A., Pirela, A., Azuero, A., Salami, A., & Poppiti, R. (2021). Post-mortem assessment of vimentin expression as a biomarker for renal tubular regeneration following acute kidney injury. Journal of Pathology and Translational Medicine, 55(6), 369–379. https://doi.org/10.4132/jptm.2021.08.03.
4. PubMed Central (PMC) +١
5. Behrouzi, A., Xia, H., Thompson, E. L., Kelley, M. R., & Fehrenbacher, J. C. (2022). Oxidative DNA damage and cisplatin neurotoxicity is exacerbated by inhibition of OGG1 glycosylase activity and APE1 endonuclease activity in sensory neurons. International Journal of Molecular Sciences, 23(3), 1909.
6. Chaudhary, P., Janmeda, P., Docea, A. O., Yeskaliyeva, B., Abdull Razis, A. F., Modu, B., & Sharifi-Rad, J. (2023). Oxidative stress, free radicals and antioxidants: Potential crosstalk in the pathophysiology of human diseases. Frontiers in Chemistry, 11, 1158198.
7. Chen, M. F., Yang, C. M., Su, C. M., & Hu, M. L. (2014). Vitamin C protects against cisplatin-induced nephrotoxicity and damage without reducing its effectiveness in C57BL/6 mice xenografted with Lewis lung carcinoma. Nutrition and Cancer, 66(7), 1085–1091.
8. Didier, A. J., Stiene, J., Fang, L., Watkins, D., Dworkin, L. D., & Creeden, J. F. (2023). Antioxidant and anti-tumor effects of dietary vitamins A, C, and E. Antioxidants, 12(3), 632.
9. Dos Santos, N. A. G., Ferreira, R. S., & Dos Santos, A. C. (2020). Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents. Food and Chemical Toxicology, 136, 111079.
10. Elmorsy, E. A., Saber, S., Hamad, R. S., Abdel-Reheim, M. A., El-Kott, A. F., AlShehri, M. A., & Youssef, M. E. (2024). Advances in understanding cisplatin-induced toxicity: Molecular mechanisms and protective strategies. European Journal of Pharmaceutical Sciences, 203, 106939.
11. Guan, J., Tong, X., Zhang, Y., Xu, F., Zhang, Y., Liang, X., & Fu, J. (2021). Nephrotoxicity induced by cisplatin is primarily due to the activation of the 5-hydroxytryptamine degradation system in proximal renal tubules. Chemico-Biological Interactions, 349, 109662.
12. Hayati, F., Hossainzadeh, M., Shayanpour, S., Abedi-Gheshlaghi, Z., & Mousavi, S. S. B. (2016). Prevention of cisplatin nephrotoxicity. Journal of Nephropharmacology, 5(1), 57.
13. Ighodaro, O. M., & Akinloye, O. A. (2018). First line defence antioxidants—superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX): Their fundamental role in the entire antioxidant defence grid. Alexandria Journal of Medicine, 54(4), 287–293.
14. Jafari, D., Esmaeilzadeh, A., Mohammadi-Kordkhayli, M., & Rezaei, N. (2019). Vitamin C and the immune system. In Nutrition and immunity (pp. 81–102).
15. Kiss, R. C., Xia, F., & Acklin, S. (2021). Targeting DNA damage response and repair to enhance therapeutic index in cisplatin-based cancer treatment. International Journal of Molecular Sciences, 22(15), 8199.
16. Lobo, V., Patil, A., Phatak, A., & Chandra, N. (2010). Free radicals, antioxidants and functional foods: Impact on human health. Pharmacognosy Reviews, 4(8), 118–126.
17. Makovec, T. (2019). Cisplatin and beyond: Molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiology and Oncology, 53(2), 148–158.
18. McSweeney, K. R., Gadanec, L. K., Qaradakhi, T., Ali, B. A., Zulli, A., & Apostolopoulos, V. (2021). Mechanisms of cisplatin-induced acute kidney injury: Pathological mechanisms, pharmacological interventions, and genetic mitigations. Cancers, 13(7), 1572. https://doi.org/10.3390/cancers13071572⁠
19. Miazek, K., Beton, K., Śliwińska, A., & Brożek-Płuska, B. (2022). The effect of β-carotene, tocopherols and ascorbic acid as antioxidant molecules on human and animal in vitro/in vivo studies: A review of research design and analytical techniques used. Biomolecules, 12(8), 1087.
20. Mohd Zaffarin, A. S., Ng, S. F., Ng, M. H., Hassan, H., & Alias, E. (2020). Pharmacology and pharmacokinetics of vitamin E: Nanoformulations to enhance bioavailability. International Journal of Nanomedicine, 9961–9974.
21. Niki, E. (2015). Evidence for beneficial effects of vitamin E. The Korean Journal of Internal Medicine, 30(5), 571–579.
22. Oh, G. S., Kim, H. J., Shen, A., Lee, S. B., Khadka, D., Pandit, A., & So, H. S. (2014). Cisplatin-induced kidney dysfunction and perspectives on improving treatment strategies. Electrolytes & Blood Pressure, 12(2), 55–65.
23. Omary, M. B., Ku, N. O., Strnad, P., & Hanada, S. (2009). Toward unraveling the complexity of simple epithelial keratins in human disease. The Journal of Clinical Investigation, 119(7), 1794–1805. https://doi.org/10.1172/JCI37762⁠
24. Ozkok, A., & Edelstein, C. L. (2014). Pathophysiology of cisplatin-induced acute kidney injury. BioMed Research International, 2014, 967826. https://doi.org/10.1155/2014/967826⁠
25. PubMed +١
26. Peres, L. A. B., & Cunha Júnior, A. D. (2013). Acute nephrotoxicity of cisplatin: Molecular mechanisms. Brazilian Journal of Nephrology, 35(4), 332–340. https://doi.org/10.5935/0101-2800.20130052⁠
27. Perše, M., & Večerić-Haler, Ž. (2018). Cisplatin-induced rodent model of kidney injury: Characteristics and challenges. BioMed Research International, 2018, 1462802.
28. Pezeshki, Z., Khosravi, A., Nekuei, M., Khoshnood, S., Zandi, E., Eslamian, M., & Nematbakhsh, M. (2017). Time course of cisplatin-induced nephrotoxicity and hepatotoxicity. Journal of Nephropathology, 6(3), 163–169.
29. Rizvi, S., Raza, S. T., Ahmed, F., Ahmad, A., Abbas, S., & Mahdi, F. (2014). The role of vitamin E in human health and some diseases. Sultan Qaboos University Medical Journal, 14(2), e157–e165.
30. Romani, A. M. (2022). Cisplatin in cancer treatment. Biochemical Pharmacology, 206, 115323.
31. Sancho-Martínez, S. M., Piedrafita, F. J., Cannata-Andía, J. B., López-Novoa, J. M., & López-Hernández, F. J. (2011). Necrotic concentrations of cisplatin activate the apoptotic machinery but inhibit effector caspases and interfere with the execution of apoptosis. Toxicological Sciences, 122(1), 73–85.
32. Schaub, J. A., Venkatachalam, M. A., & Weinberg, J. M. (2021). Proximal tubular oxidative metabolism in acute kidney injury and the transition to CKD. Kidney360, 2(2), 355–364.
33. Shehata, M. A., Abdelfatah, M. T., & Kamel, A. M. (2018). Effects of methotrexate and vitamin C on renal cortex of rats. International Journal of Pharmaceutical Research & Allied Sciences, 7(4).
34. Sivak, K. V., & Guseynov, R. G. (2020). Relationship between cytokeratins CK8/18&19 and KIM-1 level in urine with apoptosis and necrosis of nephrotheliocytes in rats with toxic nephropathy. Medical Academic Journal, 20(2), 17–26.
35. Soni, H., Kaminski, D., Gangaraju, R., & Adebiyi, A. (2018). Cisplatin-induced oxidative stress stimulates renal Fas ligand shedding. Renal Failure, 40(1), 314–322.
36. Tan, W. J., & Vlajkovic, S. M. (2023). Molecular characteristics of cisplatin-induced ototoxicity and therapeutic interventions. International Journal of Molecular Sciences, 24(22), 16545.
37. Tarladacalisir, Y. T., Kanter, M., & Uygun, M. (2008). Protective effects of vitamin C on cisplatin-induced renal damage: A light and electron microscopic study. Renal Failure, 30(1), 1–8.
38. Wu, W. F., Wang, J. N., Li, Z., Wei, B., Jin, J., Gao, L., & Meng, X. M. (2020). 7-Hydroxycoumarin protects against cisplatin-induced acute kidney injury by inhibiting necroptosis and promoting Sox9-mediated tubular epithelial cell proliferation. Phytomedicine, 69, 153202.
39. Ying, Q., & Wu, G. (2017). Molecular mechanisms involved in podocyte EMT and concomitant diabetic kidney diseases: An update. Renal Failure, 39(1), 474–483.
40. Zeng, Q., Liao, M., Li, Y., She, F., & Zhang, P. (2025). Association between dietary vitamin E intake and incident cardiovascular disease, cardiovascular, and all-cause mortality: A prospective cohort study using NHANES 2003–2018 data. International Journal of Cardiology Cardiovascular Risk and Prevention, 24, 200340